Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy

Tumori

Volumn 100, Issue 4, 2014, Pages

  Cecconetto, Lorenzo ^a   Casadei Gardini, Andrea ^a   Tenti, Elena ^a   Maltoni, Roberta ^a   Bravaccini, Sara ^a   Oboldi, Devil ^a   Zoli, Wainer ^a   Serra, Patrizia ^a   Donati, Caterina ^a   Sarti, Samanta ^a   Amadori, Dino ^a   Rocca, Andrea ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Breast cancer; Long term complete response; Metronomic chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PACLITAXEL; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; TUMOR MARKER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; CARCINOMA, DUCTAL, BREAST; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MASTECTOMY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PREDICTIVE VALUE; SECONDARY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; UPREGULATION;

ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MASTECTOMY, MODIFIED RADICAL; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PREDICTIVE VALUE OF TESTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84921690766     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1578.17238     Document Type: Article

References (16)

1. Bocci G, Nicolaou KC, Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res, 62: 6938-6943, 2002. (Pubitemid 35424084)
2. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer, 4: 423-436, 2004. (Pubitemid 38745528)
3. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum, 32: 1065-1073, 1989. (Pubitemid 19237859)
4. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res, 60: 1878-1886, 2000. (Pubitemid 30207647)
5. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, 13: 73-80, 2002. (Pubitemid 34436728)
6. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, Viale G, Goldhirsch A: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol, 17: 232-238, 2006. (Pubitemid 43160111)
7. Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, Goldhirsch A, D'Alessandro C, Cinieri S, Preda L, Colleoni M: Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs, 17: 961-967, 2006. (Pubitemid 44350615)
8. Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D'Amico M, DeCensi A, Bruzzi P: Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol, 29: 2144-2149, 2011.
9. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R: Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer, 98: 1643-1648, 2003. (Pubitemid 37238620)
10. Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, Landthaler M, Andreesen R, Reichle A: Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer, 98: 2251-2256, 2003. (Pubitemid 37392430)
11. Spieth K, Kaufmann R, Gille J: Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol, 52: 377-382, 2003. (Pubitemid 37363610)
12. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS: Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell, 7: 101-111, 2005. (Pubitemid 40126386)
13. Bocci G, Francia G, Man S, Lawler J, Kerbel RS: Thrombospondin 1, a mediator of the antiangiogenic effects of lowdose metronomic chemotherapy. Proc Natl Acad Sci USA, 100: 12917-1222, 2003.
14. Schneider BP, Miller KD: Angiogenesis of breast cancer. J Clin Oncol, 23: 1782-1790, 2005. (Pubitemid 46211430)
15. Patten SG, Adamcic U, Lacombe K, Minhas K, Skowronski K, Coomber BL: VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer, 10: 683, 2010.
16. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ: Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer, 108: 1052-1060, 2013.